Active substance |
pirfenidone |
Holder |
NV Roche SA |
Status |
Running |
Indication |
treatment of patients with advanced idiopathic pulmonary fibrosis and risk of group 3 pulmonary hypertension (i.e. pulmonary hypertension occurring secondary to lung disease and/or hypoxia) and exiting study MA29957 |
Public documents |
|
Last update |
15/06/2023 |
Esbriet
Last updated on 13/02/2024